MDRO Reporting

Carbapenem-Resistant Enterobacteriaceae (CRE)

When:  July 2018

What:  Reporting and submitting isolates within 7 days for Carbapenem-Resistant Enterobacterales (CRE) defined as any Klebsiella spp., Enterobacter spp., or Escherichia coli that is resistant to carbapenems or that produces carbapenemase; see  Download this pdf file. Laboratory CRE Reporting and Submission Guidelines  .

(Note: Reporting and submission of other healthcare-associated carabapenamse-resistant organism isolates, including other CR-genera in the order, Enterobacterales, CR-Pseudomonas spp., and CR-Acinetobacter spp., is strongly encouraged but not required; contact [email protected] for more information.)

Laboratories can report via electronic laboratory reporting, secure email to [email protected] within 7 days.

Patient information can be entered into the CRE case report form in SendSS. 

To create a SendSS authorized user account, complete a registration form at

For SendSS related questions, please email: [email protected].

CRE Isolate Submission

Background and Justification:

Candida auris: Call for Cases

Candida auris is an emerging multidrug-resistant yeast that can cause invasive infections and is associated with high mortality. C. auris can spread from patient to patient within healthcare facilities and cause prolonged healthcare-associated outbreaks.

C. auris can be misidentified as a number of different organisms when using traditional phenotypic methods for yeast identification.

When to suspect C. auris

Healthcare facilities or laboratories that suspect they have a patient with C. auris infection should contact the HAI team at GDPH ([email protected] or 404-657-2588) and CDC ([email protected]) immediately for guidance.

Background and Justification: